ClinicalTrials.gg
CompletedNCT01165138Updated Feb 14, 2018Results posted

Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

A Phase 3 interventional study of Fluticasone furoate/Vilanterol Inhalation Powder and Fluticasone Furoate Inhalation Powder in Asthma, sponsored by GlaxoSmithKline. Completed at 70 sites in 6 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-02-14.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
612
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 262 studies in Asthma by GlaxoSmithKline — 7 open to participants now, 12 under way, 7 of them phase 3. Asthma · GlaxoSmithKline.

Enrollment
30th of 238
612 · median 93
Started
2010
with 33 others
Phase 3
61 of 262
6 open now
Registered
102nd of 262
by date

Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 30th largest by enrollment of the 238 interventional ones that give a count, is one of 34 that started in 2010, is one of 61 in phase 3, and was the 102nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 262 studies in Asthma by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 262 studies in Asthma by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder and fluticasone furoate inhalation powder both administered once daily in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 12 week treatment period.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • GW642444
  • Vilanterol
  • Asthma
  • Fluticasone Furoate
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatients at least 12 years of age
  • Male and female; female subjects of must be willing to use
  • Pre-bronchodilator of 40-90% predicted normal
  • Reversibility FEV1 of at least 12% and 200mL
  • Current asthma therapy includes inhaled use for at least 12 weeks prior to first visit

Exclusion criteria

Exclusion Criteria:

  • History of life-threatening asthma during last 10 years
  • Respiratory infection or oral candidiasis
  • Asthma exacerbation requiring oral or that required overnight hospitalisation requiring additional asthma treatment
  • Uncontrolled disease or clinical abnormality
  • Allergies to study drugs or the
  • Taking another medication or prohibited medication
  • Night shift workers
  • Current smokers or subjects with a smoking history of at least 10 pack years
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
612 participants (actual)

Study arms

  • Experimental
    Fluticasone furoate/Vilanterol (GW642444)

    Fluticasone furoate/Vilanterol inhalation powder once daily for 12 weeks

    Drug: Fluticasone furoate/Vilanterol Inhalation Powder

  • Experimental
    Fluticasone Furoate

    Fluticasone furoate inhalation powder once daily for 12 weeks

    Drug: Fluticasone Furoate Inhalation Powder

  • Placebo comparator
    Placebo

    Placebo inhalation powder once daily for 12 weeks

    Drug: Placebo Inhaltion Powder

Interventions

  • DrugFluticasone furoate/Vilanterol Inhalation Powder

    Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 12 weeks

  • DrugFluticasone Furoate Inhalation Powder

    Fluticasone Furoate Inhalation Powder inhaled orally once daily for 12 weeks

  • DrugPlacebo Inhaltion Powder

    Placebo Inhaltion Powder inhaled orally once daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at Week 12

    Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as the clinic visit (pre-bronchodilator and pre-dose) FEV1measurement taken at the clinic visit while still on-treatment. Pre-dose and pre-rescue albuterol/salbutamol trough FEV1 was measured electronically by spirometry in the evening at the Baseline through Week 12 clinic visits. The highest of 3 technically acceptable measurements was recorded. Baseline was the pre-dose value obtained at Visit 3. Change from Baseline was calculated as the Week 12 value minus the Baseline value. The analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of Baseline trough FEV1, region, sex, age, and treatment group. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing m

    Time frame: Baseline and Week 12

  2. Change From Baseline in Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Week 12

    Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at the Baseline and Week 12 clinic visits. Weighted mean was calculated using the 24-hour serial FEV1 measurements that included the pre-dose assessment (within 30 minutes prior to dosing at Baseline and within 5 minutes prior to dosing at Week 12) and post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, 4, 5, 12, 16, 20, 23, and 24 hours. At each time point, the highest of 3 technically acceptable measurements was recorded. Baseline was the value obtained at Visit 3. Change from Baseline was calculated as the average Week 12 FEV1 value minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline FEV1, region, sex, age, and treatment group.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Mean Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period

    The number of inhalations of rescue albuterol/salbutamol inhalation aerosol used during the day and night was recorded by the participants in a daily electronic diary (eDiary). A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered to be rescue free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 12-week Treatment Period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.

    Time frame: Baseline and Week 12

  2. Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period

    Asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the peak expiratory flow measurement. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 12-week Treatment Period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.

    Time frame: Baseline and Week 12

  3. Change From Baseline in the Total Asthma Quality of Life Questionnaire (AQLQ) (+12) Score at Week 12/Early Withdrawal

    The AQLQ is a disease-specific, self-administered quality of life questionnaire used to evaluate the impact of asthma treatments on the quality of life of asthma sufferers. The AQLQ for 12 years and older (AQLQ \[+12\]) is a modified version of the AQLQ for use in asthma patients between the age of 12 and 70. The AQLQ contains 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). For the 32 items on the questionnaire, the response format consists of a seven-point scale, where a value of 1 indicates "total impairment" and a value of 7 indicates "no impairment." The AQLQ total score is defined as the average of the scores from all 32 questions; thus, the total score ranges from 1 (indicates "total impairment") to 7 (indicates "no impairment"). Baseline was the total score obtained at Visit 3. Change from Baseline was calculated as the total score at Week 12 minus the total score at Baseline.

    Time frame: Baseline and Week 12/Early Withdrawal

  4. Number of Participants Who Withdrew Due to Lack of Efficacy During the 12-week Treatment Period

    The number of participants whose primary reason for withdrawal was lack of efficacy was analyzed.

    Time frame: From the first dose of the study medication up to Week 12/Early Withdrawal

  5. Serial FEV1 Over 0-1 Hour Post-dose at Randomization

    Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at Randomization. Serial FEV1 measurements after 5, 15, and 30 minutes and 1 hour post-dose were assessed. At each time point, the highest of 3 technically acceptable measurements was recorded. The analysis was performed using a repeated measures model adjusted for baseline, region, sex, age, treatment group, and planned time points.

    Time frame: Randomization

Other outcomes

  1. Clinic Visit 12-hour Post-dose FEV1 at Week 12

    Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. 12-hour post-dose FEV1 measurements were taken electronically by spirometry at the Week 12 clinic visit. The highest of 3 technically acceptable measurements was recorded. The analysis was performed using an ANCOVA model with covariates of Baseline FEV1, region, sex, age, and treatment group.

    Time frame: Week 12

  2. Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Baseline

    Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at Baseline. Weighted mean was calculated using the 24-hour serial FEV1 measurements that included the pre-dose assessment (within 30 minutes prior to dosing) and post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, 4, 5, 12, 16, 20, 23, and 24 hours. At each time point, the highest of 3 technically acceptable measurements were recorded. Baseline was the value obtained at Visit 3.

    Time frame: Baseline

  3. Weighted Mean Serial FEV1 Over 0-4 Hours Post-dose at Baseline and Week 12

    Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at the Baseline and Week 12 clinic visits. Weighted mean serial FEV1 over 0-4 hours was calculated using the serial FEV1 measurements that included the pre-dose assessment (within 30 minutes prior to dosing at Baseline and within 5 minutes prior to dosing at Week 12) and post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, and 4 hours. At each time point, the highest of 3 technically acceptable measurements were recorded. Baseline was the value obtained at Visit 3.

    Time frame: Baseline and Week 12

  4. Number of Participants With Bronchodilator Effect

    Bronchodilator effect is defined as an increase of FEV1 (defined as the maximal amount of air that can be forcefully exhaled in one second) from Baseline of both 12% and 200 milliliters (mL) during 24 hours, which was evaluated using the serial FEV1 measurements at Baseline (Visit 3).

    Time frame: Baseline

  5. Mean Change From Baseline in Daily Morning (AM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period

    Peak Expiratory Flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily AM PEF over the 12-week treatment period (at Week 12) minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.

    Time frame: From Baseline up to Week 12

  6. Mean Change From Baseline in Daily Evening (PM) PEF Averaged Over the 12-week Treatment Period

    PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily PM PEF over the 12-week treatment period (at Week 12) minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.

    Time frame: From Baseline up to Week 12

  7. Change From Baseline in the Asthma Control Test (ACT) Score at Week 12

    The ACT is a 5-item questionnaire developed as a measure of the participant's asthma control. Questions are designed to be self-completed by the participant and include the following: In the past 4 weeks, "How much of the time did your asthma keep you from getting as much done at work, school or at home?", "How often have you had shortness of breath?", "How often did your asthma symptoms wake you up at night or earlier than usual in the morning?", "How often have you used your rescue inhaler or nebulizer medication (such as albuterol)?" and "How would you rate your asthma control"? The ACT total score is defined as the sum of the scores from all 5 questions, provided all questions have been answered; thus, the total score ranges from 5 (poor control of asthma) to 25 (complete control of asthma). A score of 20 or higher indicates well-controlled asthma. Change from Baseline was calculated as the total score at Week 12/Early Withdrawal minus the total score at Baseline.

    Time frame: Baseline and Week 12/Early Withdrawal

  8. Number of Participants With the Indicated Global Assessment of Change Responses at Week 4, Week 8, and Week 12/Early Withdrawal

    At the end of Week 4, Week 8, and Week 12/Early Withdrawal, the Global Assessment of Change Questionnaire that assesses changes in asthma symptoms (AS) and rescue medication use (RMU) was completed by the participants. The number of participants who chose the following answers to the questionnaire were determined: much better, somewhat better, a little better, the same, a little worse, somewhat worse, much worse (to assess the changes in asthma symptom); much less often , somewhat less often , a little less often , the same , a little more often , somewhat more often , much more often (to assess the changes in the frequency of rescue medication use).

    Time frame: Week 4, Week 8, and Week 12/Early Withdrawal

  9. Number of the Indicated Unscheduled Asthma-related Healthcare Visits During the Treatment Period

    All unscheduled asthma-related visits to a physician's office, visits to urgent care, visits to the emergency department, and hospitalizations (ICU=intensive care unit; GW=general ward) associated with severe asthma exacerbations or other asthma-related healthcare were recorded.

    Time frame: From Baseline up to Week 12/Early Withdrawal

  10. Number of Participants Who Used the Inhaler Correctly or Incorrectly at Baseline, Week 2, and Week 4

    Participants were given a demonstration of correct inhaler use (using placebo inhalers), and the participants' competence to correctly use the demonstration inhaler was then assessed.

    Time frame: Baseline (BL), Week 2 (W2), and Week 4 (W4)

  11. Number of Participants With the Indicated Reason for Incorrect Inhaler Use and Who Required Additional Instruction the Indicated Number of Times at Baseline, Week 2, and Week 4

    Participants were given a demonstration of correct inhaler use (using placebo inhalers), and the participants' competence to correctly use the demonstration inhaler was then assessed based on 3 steps: open the device, inhale the dose, and close the device. If the participants did not perform the maneuvers correctly, the step of the inhaler use that was performed incorrectly by the participants was recorded. The entire procedure was demonstrated once again. and the number of times that the participants required additional instruction (RAI) was recorded.

    Time frame: Baseline, Week 2, and Week 4

07

Results

Posted Jul 30, 2013

Participant flow

Participant flow — Overall Study
MilestoneCurrent Anti-asthma Therapy at a Fixed DosePlaceboFF 100 µg ODFF/VI 100/25 µg OD
Started0203205201
Completed0151185179
Not completed0522022
Withdrew: Adverse event0102
Withdrew: Lack of efficacy03267
Withdrew: Protocol violation0702
Withdrew: Lost to follow-up0012
Withdrew: Physician decision0676
Withdrew: Withdrawal by subject0663

Outcome measures

PrimaryMean Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at Week 12

Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as the clinic visit (pre-bronchodilator and pre-dose) FEV1measurement taken at the clinic visit while still on-treatment. Pre-dose and pre-rescue albuterol/salbutamol trough FEV1 was measured electronically by spirometry in the evening at the Baseline through Week 12 clinic visits. The highest of 3 technically acceptable measurements was recorded. Baseline was the pre-dose value obtained at Visit 3. Change from Baseline was calculated as the Week 12 value minus the Baseline value. The analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of Baseline trough FEV1, region, sex, age, and treatment group. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing m

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Liters
Mean Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at Week 12
LitersPlaceboFF 100 µg ODFF/VI 100/25 µg OD
Mean Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at Week 120.196 ± 0.03100.332 ± 0.03020.368 ± 0.0304
Statistical analysis
  • Placebo vs FF 100 µg OD · ANCOVA · p = 0.002 · Median difference (final values): 0.136 · 95% CI 0.051 to 0.222
  • Placebo vs FF/VI 100/25 µg OD · ANCOVA · p = <0.001 · Median difference (final values): 0.172 · 95% CI 0.087 to 0.258
  • FF 100 µg OD vs FF/VI 100/25 µg OD · ANCOVA · p = 0.405 · Median difference (final values): 0.036 · 95% CI -0.048 to 0.120
PrimaryChange From Baseline in Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Week 12

Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at the Baseline and Week 12 clinic visits. Weighted mean was calculated using the 24-hour serial FEV1 measurements that included the pre-dose assessment (within 30 minutes prior to dosing at Baseline and within 5 minutes prior to dosing at Week 12) and post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, 4, 5, 12, 16, 20, 23, and 24 hours. At each time point, the highest of 3 technically acceptable measurements was recorded. Baseline was the value obtained at Visit 3. Change from Baseline was calculated as the average Week 12 FEV1 value minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline FEV1, region, sex, age, and treatment group.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Liters
Change From Baseline in Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Week 12
LitersPlaceboFF 100 µg ODFF/VI 100/25 µg OD
Change From Baseline in Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Week 120.212 ± 0.04560.398 ± 0.04320.513 ± 0.0430
Statistical analysis
  • Placebo vs FF 100 µg OD · ANCOVA · p = 0.003 · Median difference (final values): 0.186 · 95% CI 0.062 to 0.310
  • Placebo vs FF/VI 100/25 µg OD · ANCOVA · p = <0.001 · Median difference (final values): 0.302 · 95% CI 0.178 to 0.426
  • FF 100 µg OD vs FF/VI 100/25 µg OD · ANCOVA · p = 0.060 · Mean difference (final values): 0.116 · 95% CI -0.005 to 0.236
SecondaryMean Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period

The number of inhalations of rescue albuterol/salbutamol inhalation aerosol used during the day and night was recorded by the participants in a daily electronic diary (eDiary). A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered to be rescue free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 12-week Treatment Period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percentage of rescue-free 24-hr periods
Mean Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period
Percentage of rescue-free 24-hr periodsPlaceboFF 100 µg ODFF/VI 100/25 µg OD
Mean Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period17.8 ± 2.2626.5 ± 2.2537.1 ± 2.26
SecondaryChange From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period

Asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the peak expiratory flow measurement. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 12-week Treatment Period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percentage of symptom-free 24-hr periods
Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period
Percentage of symptom-free 24-hr periodsPlaceboFF 100 µg ODFF/VI 100/25 µg OD
Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period14.6 ± 2.1520.4 ± 2.1332.5 ± 2.14
SecondaryChange From Baseline in the Total Asthma Quality of Life Questionnaire (AQLQ) (+12) Score at Week 12/Early Withdrawal

The AQLQ is a disease-specific, self-administered quality of life questionnaire used to evaluate the impact of asthma treatments on the quality of life of asthma sufferers. The AQLQ for 12 years and older (AQLQ \[+12\]) is a modified version of the AQLQ for use in asthma patients between the age of 12 and 70. The AQLQ contains 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). For the 32 items on the questionnaire, the response format consists of a seven-point scale, where a value of 1 indicates "total impairment" and a value of 7 indicates "no impairment." The AQLQ total score is defined as the average of the scores from all 32 questions; thus, the total score ranges from 1 (indicates "total impairment") to 7 (indicates "no impairment"). Baseline was the total score obtained at Visit 3. Change from Baseline was calculated as the total score at Week 12 minus the total score at Baseline.

Time frame:
Baseline and Week 12/Early Withdrawal
Reported as:
Least squares mean · Score on a scale
Change From Baseline in the Total Asthma Quality of Life Questionnaire (AQLQ) (+12) Score at Week 12/Early Withdrawal
Score on a scalePlaceboFF 100 µg ODFF/VI 100/25 µg OD
Change From Baseline in the Total Asthma Quality of Life Questionnaire (AQLQ) (+12) Score at Week 12/Early Withdrawal0.61 ± 0.0610.76 ± 0.0550.91 ± 0.055
SecondaryNumber of Participants Who Withdrew Due to Lack of Efficacy During the 12-week Treatment Period

The number of participants whose primary reason for withdrawal was lack of efficacy was analyzed.

Time frame:
From the first dose of the study medication up to Week 12/Early Withdrawal
Reported as:
Number · participants
Number of Participants Who Withdrew Due to Lack of Efficacy During the 12-week Treatment Period
participantsPlaceboFF 100 µg ODFF/VI 100/25 µg OD
Number of Participants Who Withdrew Due to Lack of Efficacy During the 12-week Treatment Period3267
SecondarySerial FEV1 Over 0-1 Hour Post-dose at Randomization

Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at Randomization. Serial FEV1 measurements after 5, 15, and 30 minutes and 1 hour post-dose were assessed. At each time point, the highest of 3 technically acceptable measurements was recorded. The analysis was performed using a repeated measures model adjusted for baseline, region, sex, age, treatment group, and planned time points.

Time frame:
Randomization
Reported as:
Least squares mean · Liters
Serial FEV1 Over 0-1 Hour Post-dose at Randomization
LitersPlaceboFF 100 µg ODFF/VI 100/25 µg OD
5 Minutes, n=117, 112, 1172.489 ± 0.03082.493 ± 0.03142.484 ± 0.0308
15 Minutes, n=118, 115, 1172.491 ± 0.03362.529 ± 0.03422.566 ± 0.0336
30 Minutes, n=118, 116, 1182.532 ± 0.03542.552 ± 0.03592.596 ± 0.0354
1 Hour, n=119, 116, 1192.552 ± 0.03442.571 ± 0.03502.674 ± 0.0344
Other pre-specifiedClinic Visit 12-hour Post-dose FEV1 at Week 12

Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. 12-hour post-dose FEV1 measurements were taken electronically by spirometry at the Week 12 clinic visit. The highest of 3 technically acceptable measurements was recorded. The analysis was performed using an ANCOVA model with covariates of Baseline FEV1, region, sex, age, and treatment group.

Time frame:
Week 12
Reported as:
Least squares mean · Liters
Clinic Visit 12-hour Post-dose FEV1 at Week 12
LitersPlaceboFF 100 µg ODFF/VI 100/25 µg OD
Clinic Visit 12-hour Post-dose FEV1 at Week 122.462 ± 0.05022.674 ± 0.04752.830 ± 0.0468
Other pre-specifiedWeighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Baseline

Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at Baseline. Weighted mean was calculated using the 24-hour serial FEV1 measurements that included the pre-dose assessment (within 30 minutes prior to dosing) and post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, 4, 5, 12, 16, 20, 23, and 24 hours. At each time point, the highest of 3 technically acceptable measurements were recorded. Baseline was the value obtained at Visit 3.

Time frame:
Baseline
Reported as:
Mean · Liters
Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Baseline
LitersPlaceboFF 100 µg ODFF/VI 100/25 µg OD
Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Baseline2.543 ± 0.84942.552 ± 0.75272.709 ± 0.8153
Other pre-specifiedWeighted Mean Serial FEV1 Over 0-4 Hours Post-dose at Baseline and Week 12

Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at the Baseline and Week 12 clinic visits. Weighted mean serial FEV1 over 0-4 hours was calculated using the serial FEV1 measurements that included the pre-dose assessment (within 30 minutes prior to dosing at Baseline and within 5 minutes prior to dosing at Week 12) and post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, and 4 hours. At each time point, the highest of 3 technically acceptable measurements were recorded. Baseline was the value obtained at Visit 3.

Time frame:
Baseline and Week 12
Reported as:
Mean · Liters
Weighted Mean Serial FEV1 Over 0-4 Hours Post-dose at Baseline and Week 12
LitersPlaceboFF 100 µg ODFF/VI 100/25 µg OD
Baseline, n=120, 115, 1192.563 ± 0.81942.522 ± 0.74792.693 ± 0.7626
Week 12, n=96, 105, 1092.636 ± 0.85192.657 ± 0.79122.894 ± 0.8383
Other pre-specifiedNumber of Participants With Bronchodilator Effect

Bronchodilator effect is defined as an increase of FEV1 (defined as the maximal amount of air that can be forcefully exhaled in one second) from Baseline of both 12% and 200 milliliters (mL) during 24 hours, which was evaluated using the serial FEV1 measurements at Baseline (Visit 3).

Time frame:
Baseline
Reported as:
Number · participants
Number of Participants With Bronchodilator Effect
participantsPlaceboFF 100 µg ODFF/VI 100/25 µg OD
Number of Participants With Bronchodilator Effect73 (0 to 272.0)77 (0 to 270.0)97 (0 to 62.0)
Other pre-specifiedMean Change From Baseline in Daily Morning (AM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period

Peak Expiratory Flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily AM PEF over the 12-week treatment period (at Week 12) minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.

Time frame:
From Baseline up to Week 12
Reported as:
Least squares mean · Liters per minute
Mean Change From Baseline in Daily Morning (AM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period
Liters per minutePlaceboFF 100 µg ODFF/VI 100/25 µg OD
Mean Change From Baseline in Daily Morning (AM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period-0.4 ± 2.4218.3 ± 2.4132.9 ± 2.42
Other pre-specifiedMean Change From Baseline in Daily Evening (PM) PEF Averaged Over the 12-week Treatment Period

PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily PM PEF over the 12-week treatment period (at Week 12) minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.

Time frame:
From Baseline up to Week 12
Reported as:
Least squares mean · Liters per minute
Mean Change From Baseline in Daily Evening (PM) PEF Averaged Over the 12-week Treatment Period
Liters per minutePlaceboFF 100 µg ODFF/VI 100/25 µg OD
Mean Change From Baseline in Daily Evening (PM) PEF Averaged Over the 12-week Treatment Period-1.8 ± 2.3614.1 ± 2.3426.4 ± 2.35
Other pre-specifiedChange From Baseline in the Asthma Control Test (ACT) Score at Week 12

The ACT is a 5-item questionnaire developed as a measure of the participant's asthma control. Questions are designed to be self-completed by the participant and include the following: In the past 4 weeks, "How much of the time did your asthma keep you from getting as much done at work, school or at home?", "How often have you had shortness of breath?", "How often did your asthma symptoms wake you up at night or earlier than usual in the morning?", "How often have you used your rescue inhaler or nebulizer medication (such as albuterol)?" and "How would you rate your asthma control"? The ACT total score is defined as the sum of the scores from all 5 questions, provided all questions have been answered; thus, the total score ranges from 5 (poor control of asthma) to 25 (complete control of asthma). A score of 20 or higher indicates well-controlled asthma. Change from Baseline was calculated as the total score at Week 12/Early Withdrawal minus the total score at Baseline.

Time frame:
Baseline and Week 12/Early Withdrawal
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in the Asthma Control Test (ACT) Score at Week 12
Scores on a scalePlaceboFF 100 µg ODFF/VI 100/25 µg OD
Change From Baseline in the Asthma Control Test (ACT) Score at Week 122.5 ± 0.263.8 ± 0.234.4 ± 0.23
Other pre-specifiedNumber of Participants With the Indicated Global Assessment of Change Responses at Week 4, Week 8, and Week 12/Early Withdrawal

At the end of Week 4, Week 8, and Week 12/Early Withdrawal, the Global Assessment of Change Questionnaire that assesses changes in asthma symptoms (AS) and rescue medication use (RMU) was completed by the participants. The number of participants who chose the following answers to the questionnaire were determined: much better, somewhat better, a little better, the same, a little worse, somewhat worse, much worse (to assess the changes in asthma symptom); much less often , somewhat less often , a little less often , the same , a little more often , somewhat more often , much more often (to assess the changes in the frequency of rescue medication use).

Time frame:
Week 4, Week 8, and Week 12/Early Withdrawal
Reported as:
Number · participants
Number of Participants With the Indicated Global Assessment of Change Responses at Week 4, Week 8, and Week 12/Early Withdrawal
participantsPlaceboFF 100 µg ODFF/VI 100/25 µg OD
Week 4, AS - Much better, n=174, 198, 191344765
Week 4, AS - Somewhat better, n=174, 198, 191456561
Week 4, AS - A little better, n=174, 198, 191424737
Week 4, AS - The same, n=174, 198, 191332923
Week 4, AS - A little worse, n=174, 198, 1916103
Week 4, AS - Somewhat worse, n=174, 198, 191802
Week 4, AS - Much worse, n=174, 198, 191600
Week 4, RMU - Much less often, n=174, 198, 191395975
Week 4, RMU - Somewhat less often, n=174, 198, 191404851
Week 4, RMU - A little less often, n=174, 198, 191354932
Week 4, RMU - The same, n=174, 198, 191313328
Week 4, RMU - A little more often, n=174, 198, 1911364
Week 4, RMU - Somewhat more often, n=174, 198, 1911131
Week 4, RMU - Much more often, n=174, 198, 191500
Week 8, AS - Much better, n=159, 192, 184365469
Week 8, AS - Somewhat better, n=159, 192, 184446063
Week 8, AS - A little better, n=159, 192, 184384022
Week 8, AS - The same, n=159, 192, 184293324
Week 8, AS - A little worse, n=159, 192, 184753
Week 8, AS - Somewhat worse, n=159, 192, 184402
Week 8, AS - Much worse, n=159, 192, 184101
Week 8, RMU - Much less often, n=159, 191, 184376586
Week 8, RMU - Somewhat less often, n=159, 191, 184324843
Week 8, RMU - A little less often, n=159, 191, 184373425
Week 8, RMU - The same, n=159, 191, 184363923
Week 8, RMU - A little more often, n=159, 191, 1841215
Week 8, RMU - Somewhat more often, n=159, 191, 184440
Week 8, RMU - Much more often, n=159, 191, 184102
Week 12, AS - Much better, n=152, 187, 182386686
Week 12, AS - Somewhat better, n=152, 187, 182374952
Week 12, AS - A little better, n=152, 187, 182293513
Week 12, AS - The same, n=152, 187, 182293023
Week 12, AS - A little worse, n=152, 187, 182977
Week 12, AS - Somewhat worse, n=152, 187, 182601
Week 12, AS - Much worse, n=152, 187, 182400
Week 12, RMU - Much less often, n=150, 187, 182427689
Week 12, RMU -Somewhat less often, n=150, 187, 182324643
Week 12, RMU -A little less often, n=150, 187, 182242521
Week 12, RMU - The same, n=150, 187, 182343223
Week 12, RMU -A little more often, n=150, 187, 1821265
Week 12, RMU -Somewhat more often, n=150, 187, 182311
Week 12, RMU - Much more often, n=150, 187, 182310
Other pre-specifiedNumber of the Indicated Unscheduled Asthma-related Healthcare Visits During the Treatment Period

All unscheduled asthma-related visits to a physician's office, visits to urgent care, visits to the emergency department, and hospitalizations (ICU=intensive care unit; GW=general ward) associated with severe asthma exacerbations or other asthma-related healthcare were recorded.

Time frame:
From Baseline up to Week 12/Early Withdrawal
Reported as:
Mean · Number of visits
Number of the Indicated Unscheduled Asthma-related Healthcare Visits During the Treatment Period
Number of visitsPlaceboFF 100 µg ODFF/VI 100/25 µg OD
Number of Home Visits (Day)0.0 ± 0.000.0 ± 0.000.0 ± 0.00
Number of Home Visits (Night)0.0 ± 0.000.0 ± 0.000.0 ± 0.00
Number of Physician Office/Practice Visits0.0 ± 0.240.0 ± 0.390.0 ± 0.10
Number of Urgent Care/Outpatient Clinic Visits0.0 ± 0.070.0 ± 0.070.0 ± 0.00
Number of Emergency Room Visits0.0 ± 0.000.0 ± 0.000.0 ± 0.00
Number of Inpatient Hospitalization Days (ICU)0.0 ± 0.000.0 ± 0.000.0 ± 0.00
Number of Inpatient Hospitalization (GW) Days0.0 ± 0.000.0 ± 0.000.0 ± 0.00
Other pre-specifiedNumber of Participants Who Used the Inhaler Correctly or Incorrectly at Baseline, Week 2, and Week 4

Participants were given a demonstration of correct inhaler use (using placebo inhalers), and the participants' competence to correctly use the demonstration inhaler was then assessed.

Time frame:
Baseline (BL), Week 2 (W2), and Week 4 (W4)
Reported as:
Number · participants
Number of Participants Who Used the Inhaler Correctly or Incorrectly at Baseline, Week 2, and Week 4
participantsPlaceboFF 100 µg ODFF/VI 100/25 µg OD
BL: Used Inhaler Correctly, n=203, 205, 201194196188
BL: Used Inhaler Incorrectly, n=203, 205, 2019913
W2: Used Inhaler Correctly, n=190, 203, 200190203200
W2: Used Inhaler Incorrectly, n=190, 203, 200000
W4: Used Inhaler Correctly, n=175, 199, 195175199195
W4: Used Inhaler Incorrectly, n=175, 199, 195000
Other pre-specifiedNumber of Participants With the Indicated Reason for Incorrect Inhaler Use and Who Required Additional Instruction the Indicated Number of Times at Baseline, Week 2, and Week 4

Participants were given a demonstration of correct inhaler use (using placebo inhalers), and the participants' competence to correctly use the demonstration inhaler was then assessed based on 3 steps: open the device, inhale the dose, and close the device. If the participants did not perform the maneuvers correctly, the step of the inhaler use that was performed incorrectly by the participants was recorded. The entire procedure was demonstrated once again. and the number of times that the participants required additional instruction (RAI) was recorded.

Time frame:
Baseline, Week 2, and Week 4
Reported as:
Number · participants
Number of Participants With the Indicated Reason for Incorrect Inhaler Use and Who Required Additional Instruction the Indicated Number of Times at Baseline, Week 2, and Week 4
participantsPlaceboFF 100 µg ODFF/VI 100/25 µg OD
BL: Opened the Device Incorrectly, n= 9, 9, 13846
BL: Inhaled the Dose Incorrectly, n= 9, 9, 13156
BL: Closed the Device Incorrectly, n= 9, 9, 13101
BL: RAI once, n= 9, 9, 13958
BL: RAI 2 Times, n= 9, 9, 13044
BL: RAI 3 Times, n= 9, 9, 13001
BL: RAI >3 Times, n= 9, 9, 13000
W2: Opened the Device Incorrectly, n= 0, 0, 0NANANA
W2: Inhaled the Dose Incorrectly, n= 0, 0, 0NANANA
W2: Closed the Device Incorrectly, n= 0, 0, 0NANANA
W2: RAI once, n= 0, 0, 0NANANA
W2: RAI 2 Times, n= 0, 0, 0,NANANA
W2: RAI 3 Times, n= 0, 0, 0NANANA
W4: Opened the Device Incorrectly, n= 0, 0, 0NANANA
W4: Inhaled the Dose Incorrectly, n= 0, 0, 0NANANA
W4: Closed the Device Incorrectly, n= 0, 0, 0NANANA
W4: RAI once, n= 0, 0, 0NANANA
W4: RAI 2 Times, n= 0, 0, 0NANANA
W4: RAI 3 Times, n= 0, 0, 0NANANA
W4: RAI >3 Times, n= 0, 0, 0NANANA

Adverse events

Collected over Serious Adverse Events (SAEs) and non-serious AEs were collected from the first dose of study medication up to Week 12/Early Withdrawal.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/203 (0%)22/203 (10.8%)
FF 100 µg OD—1/205 (0.5%)20/205 (9.8%)
FF/VI 100/25 µg OD—0/201 (0%)29/201 (14.4%)
Most frequent serious events
Most frequent serious events
EventPlaceboFF 100 µg ODFF/VI 100/25 µg OD
PancreatitisGastrointestinal disorders0/2031/2050/201
Most frequent other events
Most frequent other events
EventPlaceboFF 100 µg ODFF/VI 100/25 µg OD
NasopharyngitisInfections and infestations15/20314/20520/201
HeadacheNervous system disorders8/2039/20510/201

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboFF 100 µg ODFF/VI 100/25 µg ODTotal
Mean38.1 ± 16.4940.4 ± 16.7840.7 ± 16.3839.7 ± 16.56
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboFF 100 µg ODFF/VI 100/25 µg ODTotal
Female111126116353
Male927985256
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboFF 100 µg ODFF/VI 100/25 µg ODTotal
African American/African Heritage14161343
American Indian or Alaska Native0101
Asian - Japanese Heritage19161550
Asian - South East Asian Heritage0011
White - Arabic/North African Heritage0101
White - White/Caucasian/European Heritage169170172511
Mixed Race1102
08

Study locations

70 sites
  • GSK Investigational Site
    Bell Gardens, California 90201, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Long Beach, California 90808, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    Newport Beach, California 92663, United States
  • GSK Investigational Site
    Riverside, California 92506, United States
  • GSK Investigational Site
    Roseville, California 95661, United States
  • GSK Investigational Site
    San Diego, California 92120, United States
  • GSK Investigational Site
    Miami, Florida 33173, United States
  • GSK Investigational Site
    Normal, Illinois 61761, United States
  • GSK Investigational Site
    River Forest, Illinois 60305, United States
  • GSK Investigational Site
    Columbia, Maryland 21044, United States
  • GSK Investigational Site
    Rolla, Missouri 65401, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73112, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73120, United States
  • GSK Investigational Site
    Lake Oswego, Oregon 97035, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Portland, Oregon 97213, United States
  • GSK Investigational Site
    Orangeburg, South Carolina 29118, United States
  • GSK Investigational Site
    Austin, Texas 78756, United States
  • GSK Investigational Site
    Sugar Land, Texas 77479, United States
  • GSK Investigational Site
    Murray, Utah 84107, United States
  • GSK Investigational Site
    Mannheim, Baden-Wuerttemberg 68161, Germany
  • GSK Investigational Site
    Oranienburg, Brandenburg 16515, Germany
  • GSK Investigational Site
    Frankfurt am Main, Hessen 60596, Germany
  • GSK Investigational Site
    Gelnhausen, Hessen 63571, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01307, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Berlin, 10789, Germany
  • GSK Investigational Site
    Berlin, 12165, Germany
  • GSK Investigational Site
    Berlin, 14057, Germany
  • GSK Investigational Site
    Hamburg, 20354, Germany
  • GSK Investigational Site
    Fukuoka, 811-1394, Japan
  • GSK Investigational Site
    Hiroshima, 732-0052, Japan
  • GSK Investigational Site
    Hokkaido, 064-0801, Japan
  • GSK Investigational Site
    Hyogo, 672-8048, Japan
  • GSK Investigational Site
    Ishikawa, 920-8530, Japan
  • GSK Investigational Site
    Kagawa, 762-0031, Japan
  • GSK Investigational Site
    Kanagawa, 252-0143, Japan
  • GSK Investigational Site
    Kyoto, 603-8161, Japan
  • GSK Investigational Site
    Okinawa, 901-2132, Japan
  • GSK Investigational Site
    Tokyo, 158-0083, Japan
  • GSK Investigational Site
    Tokyo, 171-0014, Japan
  • GSK Investigational Site
    Tokyo, 194-0023, Japan
  • GSK Investigational Site
    Tarnow, 33-100, Poland
  • GSK Investigational Site
    Tczew, 83-110, Poland
  • GSK Investigational Site
    Wroclaw, 53-301, Poland
  • GSK Investigational Site
    Zawadzkie, 47-120, Poland
  • GSK Investigational Site
    Bucharest, 020674, Romania
  • GSK Investigational Site
    Cluj Napoca, 400371, Romania
  • GSK Investigational Site
    Craiova, 200642, Romania
  • GSK Investigational Site
    Deva, 330084, Romania
  • GSK Investigational Site
    Pitesti, 110084, Romania
  • GSK Investigational Site
    Ploiesti, 100550, Romania
  • GSK Investigational Site
    Suceava, 720284, Romania
  • GSK Investigational Site
    Timisoara, 300310, Romania
  • GSK Investigational Site
    Dnipropetrovsk, 49006, Ukraine
  • GSK Investigational Site
    Dnipropetrovsk, 49051, Ukraine
  • GSK Investigational Site
    Ivano-Frankivsk, 76018, Ukraine
  • GSK Investigational Site
    Kharkiv, 61035, Ukraine
  • GSK Investigational Site
    Kiev, 03680, Ukraine
  • GSK Investigational Site
    Kyiv, 02091, Ukraine
  • GSK Investigational Site
    Kyiv, 02660, Ukraine
  • GSK Investigational Site
    Kyiv, 03038, Ukraine
  • GSK Investigational Site
    Kyiv, 03115, Ukraine
  • GSK Investigational Site
    Kyiv, 04201, Ukraine
  • GSK Investigational Site
    Simferopol, 95043, Ukraine
  • GSK Investigational Site
    Zaporizhia, 69076, Ukraine
09

References and documents

Publications

  • O'Byrne PM, Jacques L, Goldfrad C, Kwon N, Perrio M, Yates LJ, Busse WW. Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. Respir Res. 2016 Nov 24;17(1):157. doi: 10.1186/s12931-016-0473-x. PubMed 27881132 ↗
  • Gross AS, Goldfrad C, Hozawa S, James MH, Clifton CS, Sugiyama Y, Jacques L. Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials. BMC Pulm Med. 2015 Dec 24;15:165. doi: 10.1186/s12890-015-0159-z. PubMed 26704701 ↗
  • Bleecker ER, Lotvall J, O'Byrne PM, Woodcock A, Busse WW, Kerwin EM, Forth R, Medley HV, Nunn C, Jacques L, Bateman ED. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. J Allergy Clin Immunol Pract. 2014 Sep-Oct;2(5):553-61. doi: 10.1016/j.jaip.2014.02.010. Epub 2014 Apr 24. PubMed 25213048 ↗
  • Svedsater H, Jacques L, Goldfrad C, Bleecker ER. Ease of use of the ELLIPTA dry powder inhaler: data from three randomised controlled trials in patients with asthma. NPJ Prim Care Respir Med. 2014 Jun 26;24:14019. doi: 10.1038/npjpcrm.2014.19. No abstract available. PubMed 24966061 ↗
  • Svedsater H, Dale P, Garrill K, Walker R, Woepse MW. Qualitative assessment of attributes and ease of use of the ELLIPTA dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med. 2013 Dec 7;13:72. doi: 10.1186/1471-2466-13-72. PubMed 24314123 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 1 year 9 months after primary completion. A results delay was requested in May 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2010
First posted
Jul 19, 2010
Start
Aug 20, 2010
Primary completionActual
Oct 1, 2011
CompletionActual
Oct 19, 2011
Results delay requested
May 24, 2012
Results first posted
Jul 30, 2013
Last update
Feb 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01165138
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 19, 2010
Start date
Aug 20, 2010
Primary completion
Oct 1, 2011
Completion
Oct 19, 2011
Results posted
Jul 30, 2013
Last update
Feb 14, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion